Participated · Equity · Jun 2026

Flipflow provides a unified competitive intelligence platform that monitors millions of products across tens of countries and thousands of retailers, transforming large-scale market data into actionable insights for commercial, trade marketing and e-commerce teams. Its platform offers real-time capabilities including full-store assortment analysis, price and promotion monitoring, digital visibility and execution, and control of distribution and grey-market activity. The company has announced enterprise customers in FMCG, beauty and electronics such as Nestlé, Unilever, L’Oréal and ISDIN and already operates in Spain and Latin America. This year Flipflow launched Tyrell AI, an autonomous agent that analyzes market signals 24/7 and prescribes prioritized actions to commercial and marketing teams; development of Tyrell involved collaboration with Google on AI. Flipflow is using recent funding to accelerate technology development and drive international expansion into Northern Europe and the U.S. The company positions itself as a central intelligence layer to enable faster, proactive decision-making in a fragmented retail landscape.

Participated · Series B · May 2026

Lexroom.ai develops AI infrastructure for legal professionals using a data-first approach grounded in a proprietary database of over six million verified legal sources, including legislation, case law and regulatory materials. The platform is designed to reduce fabrications and reliability issues in generative AI by structuring continuously updated source material for legal research and retrieval. Lexroom reports more than 8,000 law firm and corporate legal team customers, with most users engaging daily. Financially, the company has raised over $73 million to date after closing a $50 million Series B led by Left Lane Capital. The new capital will fund expansion into civil law markets across Europe, starting with Spain and Germany, and support building local teams and jurisdiction-specific capabilities in partnership with firms in those markets.

Participated · Equity · Apr 2026

Founded in 2023, Crescenta is a digital asset manager focused on enabling investment in private equity funds in Spain. The firm has described itself as profitable and says it has met the business plan established at its founding. Crescenta has attracted repeat backing from investors including Kfund and FJ Labs, with Acurio Ventures joining in 2025 and Endeavor Catalyst entering in the latest round. Management has set growth targets to reach €1 billion in assets under management and 20,000 customers by 2027. To support that expansion, the company plans new product launches, internationalization and entry into additional customer segments. The recent capital raise is intended to accelerate execution of this more ambitious plan.

Participated · Equity · Jan 2026

Lookiero Outfittery Group runs a digital personal shopping service that blends advanced personalisation algorithms with a network of professional shoppers to curate fashion boxes for customers. The company leverages proprietary recommendation models to match individual preferences, then ships tailored outfits to users across its 12-country footprint. In 2025 it completed the technological and logistical integration of the formerly separate Lookiero and Outfittery operations, enabling a unified platform and improved operational efficiency. That integration helped Lookiero achieve positive EBITDA, marking an important profitability milestone. With fresh capital, management plans to deepen AI capabilities for personalisation, demand forecasting, and supply planning while continuing to rely on human stylists for a hybrid service experience. The firm also aims to capture additional merger synergies to further boost margins and customer satisfaction.

Participated · Series A · Oct 2025

Founded in 2021 by Alexandros Pantalis and Adèle James, Phagos engineers bacteriophage (phage) treatments through a proprietary platform that combines microbiology with artificial intelligence. Its patented AI analyses complete phage and bacterial genomes to predict interactions and design precise, adaptable therapies as pathogens evolve. The company’s first commercial focus is veterinary medicine, where it has already secured regulatory authorisation to market personalised phage-based treatments aimed at reducing antibiotic use in livestock. Longer term, Phagos intends to expand these solutions to human health applications. With antimicrobial resistance driving millions of deaths and heavy economic costs, management positions the technology as a scalable global standard for bacterial infection control. The recent €25 million Series A financing provides capital to scale veterinary product deployment, advance the next generation of its AI, and grow the team to support market launches and international expansion. No operating metrics such as revenue or user counts were disclosed in the article.